PMID- 27105868
OWN - NLM
STAT- MEDLINE
DCOM- 20170731
LR  - 20220310
IS  - 1590-3729 (Electronic)
IS  - 0939-4753 (Linking)
VI  - 26
IP  - 5
DP  - 2016 May
TI  - Low dose resveratrol improves cerebrovascular function in type 2 diabetes 
      mellitus.
PG  - 393-9
LID - S0939-4753(16)00045-4 [pii]
LID - 10.1016/j.numecd.2016.03.003 [doi]
AB  - BACKGROUND AND AIMS: Progressive microvascular dysfunction in type 2 diabetes 
      mellitus (T2DM) may impair the ability of cerebral vessels to supply blood to 
      brain regions during local metabolic demand, thereby increasing risks of 
      dementia. Having previously demonstrated that resveratrol can enhance vasodilator 
      function in the systemic circulation, we hypothesised that resveratrol could 
      similarly benefit the cerebral circulation. We aimed to determine the most 
      efficacious dose of resveratrol to improve cerebral vasodilator responsiveness 
      (CVR) in T2DM. METHODS AND RESULTS: In a double-blind, placebo-controlled, 
      balanced crossover intervention, 36 dementia-free, non-insulin dependent T2DM 
      older adults (49-78 years old) consumed single doses of synthetic 
      trans-resveratrol (0, 75, 150, and 300 mg) at weekly intervals. Transcranial 
      Doppler ultrasound was used to assess CVR to a hypercapnic stimulus, both before 
      and 45 min after treatment. CVR, measured bilaterally in the middle cerebral 
      arteries (MCA) and posterior cerebral arteries (PCA), was expressed as the 
      percentage change in mean blood flow velocity from baseline to the peak velocity 
      attained during hypercapnia. Resveratrol consumption increased CVR in the MCA; 
      mean within-individual changes for each dose from placebo were 13.8 +/- 3.5% for 
      75 mg (P = 0.001), 8.9 +/- 3.5% for 150 mg (P = 0.016), and 13.7 +/- 3.3% for 300 mg 
      (P < 0.001); only the 75 mg dose was efficacious in the PCA (13.2 +/- 4.5%, 
      P = 0.016). CONCLUSIONS: Our results provide the first clinical evidence of an 
      acute enhancement of vasodilator responsiveness in cerebral vessels following 
      consumption of resveratrol in this population who are known to have endothelial 
      dysfunction and sub-clinical cognitive impairment. Importantly, maximum 
      improvement was observed with the lowest dose used. CLINICAL TRIAL REGISTRATION: 
      ACTRN12614000891628 (www.anzctr.org.au).
CI  - Copyright (c) 2016 The Italian Society of Diabetology, the Italian Society for the 
      Study of Atherosclerosis, the Italian Society of Human Nutrition, and the 
      Department of Clinical Medicine and Surgery, Federico II University. Published by 
      Elsevier B.V. All rights reserved.
FAU - Wong, R H X
AU  - Wong RH
AD  - University of Newcastle, School of Biomedical Sciences & Pharmacy, Clinical 
      Nutrition Research Centre, University Drive, Callaghan, New South Wales 2308, 
      Australia.
FAU - Nealon, R S
AU  - Nealon RS
AD  - University of Newcastle, School of Biomedical Sciences & Pharmacy, Clinical 
      Nutrition Research Centre, University Drive, Callaghan, New South Wales 2308, 
      Australia.
FAU - Scholey, A
AU  - Scholey A
AD  - Swinburne University, Centre for Human Psychopharmacology, Hawthorn, Victoria 
      3122, Australia.
FAU - Howe, P R C
AU  - Howe PR
AD  - University of Newcastle, School of Biomedical Sciences & Pharmacy, Clinical 
      Nutrition Research Centre, University Drive, Callaghan, New South Wales 2308, 
      Australia. Electronic address: peter.howe@newcastle.edu.au.
LA  - eng
SI  - ANZCTR/ACTRN12614000891628
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20160314
PL  - Netherlands
TA  - Nutr Metab Cardiovasc Dis
JT  - Nutrition, metabolism, and cardiovascular diseases : NMCD
JID - 9111474
RN  - 0 (Stilbenes)
RN  - Q369O8926L (Resveratrol)
SB  - IM
MH  - Aged
MH  - Blood Flow Velocity/drug effects
MH  - Cerebrovascular Circulation/*drug effects
MH  - Cerebrovascular Disorders/diagnostic imaging/etiology/physiopathology/*prevention 
      & control
MH  - Cognition/drug effects
MH  - Cognition Disorders/etiology/physiopathology/prevention & control/psychology
MH  - Cross-Over Studies
MH  - Diabetes Mellitus, Type 2/complications/diagnosis/*drug therapy
MH  - Diabetic Angiopathies/diagnostic imaging/etiology/physiopathology/*prevention & 
      control
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Middle Cerebral Artery/diagnostic imaging/*drug effects/physiopathology
MH  - Posterior Cerebral Artery/diagnostic imaging/*drug effects/physiopathology
MH  - Resveratrol
MH  - Stilbenes/*administration & dosage/adverse effects
MH  - Time Factors
MH  - Treatment Outcome
MH  - Ultrasonography, Doppler, Transcranial
MH  - Vasodilation/*drug effects
MH  - Victoria
OTO - NOTNLM
OT  - Cerebrovascular circulation
OT  - Diabetes mellitus
OT  - Nutrition
OT  - Vasodilatation
EDAT- 2016/04/24 06:00
MHDA- 2017/08/02 06:00
CRDT- 2016/04/24 06:00
PHST- 2015/12/21 00:00 [received]
PHST- 2016/03/02 00:00 [revised]
PHST- 2016/03/05 00:00 [accepted]
PHST- 2016/04/24 06:00 [entrez]
PHST- 2016/04/24 06:00 [pubmed]
PHST- 2017/08/02 06:00 [medline]
AID - S0939-4753(16)00045-4 [pii]
AID - 10.1016/j.numecd.2016.03.003 [doi]
PST - ppublish
SO  - Nutr Metab Cardiovasc Dis. 2016 May;26(5):393-9. doi: 
      10.1016/j.numecd.2016.03.003. Epub 2016 Mar 14.